Literature DB >> 12937370

Elvarex compression garments in the management of lymphoedema.

Sylvie Hampton.   

Abstract

Lymphoedema is a progressive and debilitating disorder, caused by malfunction of the lymphatic system. It is characterized by chronic swelling, usually of a limb but it can also affect other parts of the body. It is not curable but can be reduced and controlled. The mainstay of management is physical decongestive treatment, of which compression therapy is one of the four elements. The simplest and most cost-effective method of applying compression is with elastic compression garments. Essential for their success are a perfect fit and appropriate selection of compression class and stocking material. Elvarex, manufactured by JOBST, is a range of custom-made compression garments for both upper and lower limbs, available in a wide variety of styles and options. The flat knitting process provides superior fit and effective long-term management of lymphoedema.

Entities:  

Mesh:

Year:  2003        PMID: 12937370     DOI: 10.12968/bjon.2003.12.15.11425

Source DB:  PubMed          Journal:  Br J Nurs        ISSN: 0966-0461


  3 in total

1.  Breast cancer-related lymphedema: comparing direct costs of a prospective surveillance model and a traditional model of care.

Authors:  Nicole L Stout; Lucinda A Pfalzer; Barbara Springer; Ellen Levy; Charles L McGarvey; Jerome V Danoff; Lynn H Gerber; Peter W Soballe
Journal:  Phys Ther       Date:  2011-09-15

Review 2.  Compression therapy for non-venous leg ulcers: Current viewpoint.

Authors:  Eran Shavit; Afsaneh Alavi
Journal:  Int Wound J       Date:  2019-10-13       Impact factor: 3.315

3.  Physiotherapeutic stimulation: Early prevention of lymphedema following axillary lymph node dissection for breast cancer treatment.

Authors:  Almir José Sarri; Sonia Marta Moriguchi; Rogério Dias; Stela Verzinhasse Peres; Eduardo Tinóis DA Silva; Kátia Hiromoto Koga; Angelo Gustavo Zucca Matthes; Marcelo José Dos Santos; Euclides Timóteo DA Rocha; Raphael Luiz Haikel
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.